Literature DB >> 508566

Serum immunoglobulins G, A, M, D and E concentrations in lymphomas.

P L Amlot, L Green.   

Abstract

Serum immunoglobulin levels were measured in 105 patients with untreated Hodgkin's disease (HD) and 80 with non-HD lymphomas. Significant increases in IgG and IgE occurred in the whole HD group. When compared with the histological types of HD, increases of IgG, IgA AND IgE were seen in nodular sclerosis and of IgE alone in mixed-cellularity and lymphocyte-predominant types. In relation to the stage of disease spread, increases of IgG, IgA AND IgE occurred in Stages II and III, while in Stage IV, although IgE was raised, IgM in males and IgD fell significantly. Paired serum samples taken 10-14 months apart showed falls of IgM and IgD after radiotherapy, and of all Ig classes except IgD after chemotherapy. Decreased levels of IgM in females, IgG and IgA were found in the non-HD lymphomas. When analysed in terms of lymphnode histology, decreased IgG, IgA, IgM and IgE occurred in well differentiated lymphocytic lymphomas, decreased IgA alone in poorly differentiated lymphocytic lymphomas and decreased IgD in nodular types of lymphoma.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 508566      PMCID: PMC2010049          DOI: 10.1038/bjc.1979.191

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  THE ROUTE OF RE-CIRCULATION OF LYMPHOCYTES IN THE RAT.

Authors:  J L GOWANS; E J KNIGHT
Journal:  Proc R Soc Lond B Biol Sci       Date:  1964-01-14

2.  The immunoglobulins in Hodgkin's disease.

Authors:  D J Wagener; P J Van Munster; C Haanen
Journal:  Eur J Cancer       Date:  1976-09       Impact factor: 9.162

3.  The immunoglobulins in Hodgkin's disease.

Authors:  J M Goldman; J R Hobbs
Journal:  Immunology       Date:  1967-10       Impact factor: 7.397

4.  The correlation of serum IgD concentration with Gm allotype.

Authors:  P D Walzer; H G Kunkel
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

5.  Immunoglobulin D in serum, body fluids and lymphoid tissues.

Authors:  D S Rowe; P A Crabbé; M W Turner
Journal:  Clin Exp Immunol       Date:  1968-07       Impact factor: 4.330

6.  [Quantitative immunoglobulin determination (IgA, IgG, IgM) in lymphogranulomatosis].

Authors:  D Sailer; H Lutz; G Hartwich
Journal:  Verh Dtsch Ges Inn Med       Date:  1973

7.  Serum immunoglobulin E levels in patients with neoplastic disease.

Authors:  T A Waldmann; J M Bull; R M Bruce; S Broder; M C Jost; S T Balestra; M E Suer
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

8.  Immunoglobulin changes in disease: quantitation on the basis of heavy polypeptide chains, IgG (gammaG), IgA (gammaA), and IgM (gammaM), and of light polypeptide chains, type K (I) and type L (II).

Authors:  E M McKelvey; J L Fahey
Journal:  J Clin Invest       Date:  1965-11       Impact factor: 14.808

9.  The pathology and nomenclature of Hodgkin's disease.

Authors:  R J Lukes; J J Butler
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

10.  Serum IgD and IgE concentrations in immunodeficiency diseases.

Authors:  R H Buckley; S A Fiscus
Journal:  J Clin Invest       Date:  1975-01       Impact factor: 14.808

View more
  5 in total

Review 1.  Immunoglobulin D: properties, measurement, and clinical relevance.

Authors:  A O Vladutiu
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Abnormalities of in vitro immunoglobulin synthesis by peripheral blood lymphocytes from untreated patients with Hodgkin's disease.

Authors:  S Romagnani; G F Del Prete; E Maggi; G Bellesi; G Biti; P L Rossi Ferrini; M Ricci
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

3.  Impaired antibody responses to a pneumococcal polysaccharide vaccine in patients with non-Hodgkin's lymphoma in remission.

Authors:  O F Ballester; M Shurafa; H Toben; K S Kumar; C L Burek
Journal:  J Clin Immunol       Date:  1981-04       Impact factor: 8.317

4.  Antibody responses of splenectomized patients with non-Hodgkin's lymphoma to immunization with polyvalent pneumococcal vaccines.

Authors:  S Petrasch; O Kühnemund; A Reinacher; M Uppenkamp; R Reinert; W Schmiegel; R Lütticken; G Brittinger
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

5.  First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the blood-brain barrier.

Authors:  Jun Toyohara; Muneyuki Sakata; Kenji Ishibashi; Pascalle Mossel; Masamichi Imai; Kei Wagatsuma; Tetsuro Tago; Etsuko Imabayashi; Nicola A Colabufo; Gert Luurtsema; Kenji Ishii
Journal:  Ann Nucl Med       Date:  2021-08-08       Impact factor: 2.668

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.